Guide
An earlier version of this page compared the cheapest compounded semaglutide with an approved oral tablet at a flat $149. That is the price at 1.5 and 4 mg only. The 9 and 25 mg maintenance doses are $299, and the $149 rate on 4 mg ends on 31 August 2026.
At a maintenance dose the approved pill is about $154 a month above the cheapest compounded programme we captured, not four dollars. We publish this as COR-013 because it is the starter-price error this site documents in others.
The $149 rate on this page is not open-ended. The $149 rate covers 1.5 mg and 4 mg. The 4 mg price rises to $199 after this date. It stops applying on 2026-08-31, in 28 days.
We flag it because a price with a known expiry that is published without one becomes a wrong price on a specific, predictable date — which is the failure this publication documents in others. Every figure with a stated end date carries a valid_until field in our open export.
Wegovy Cost Without Insurance in 2026: Every Route Priced
Without insurance, Wegovy is $349 a month through NovoCare direct against roughly $1,349 at retail list. The approved oral semaglutide tablet is $149. The cheapest compou
Without insurance, Wegovy is $349 a month through NovoCare direct against roughly $1,349 at retail list. The approved oral semaglutide tablet is $149. The cheapest compounded semaglutide we read at source is $145 flat — about $154 a month at a maintenance dose below the approved pill, and without a trial of its own.
What does each cash route cost?
| Route | Monthly | Twelve months | Evidence |
|---|---|---|---|
| Commercial cover plus savings offer | $25 | $300 | Capped at $100/month in savings |
| Medicare GLP-1 Bridge | $50 | $600 | Reported |
| Approved oral tablet, 1.5 or 4 mg | $149 | — | Captured at source — 4 mg rises to $199 after 31 Aug 2026 |
| Approved oral tablet, 9 or 25 mg maintenance | $299 | $3,588 | Captured at source |
| Compounded, 12-month, flat at every dose | $145 | $1,740 | Captured at source |
| Compounded, month-to-month, flat | $165 | $1,980 | Captured at source |
| Brand Wegovy pen, new-patient intro | $199 | — | First two fills only, to 31 Dec 2026 |
| Brand Wegovy pen, 0.25–2.4 mg | $349 | $4,188 | Captured at source |
| Brand Wegovy HD 7.2 mg | $399 | $4,788 | Captured at source |
| Brand Wegovy, retail list | ~$1,349 | ~$16,188 | Third-party claim |
| Compounded tirzepatide, for comparison | $186 | $2,232 | Captured at source |
Read the dose column. The approved oral tablet is a ladder, not a flat rate: $149 at 1.5 and 4 mg, $299 at 9 and 25 mg. We published it as a flat $149 and corrected that on 4 August 2026 — COR-013. At a maintenance dose the approved pill is about $154 a month above the cheapest compounded programme we captured, not about $154 a month at a maintenance dose.
In late 2024 the gap between brand Wegovy and a compounded programme was several hundred dollars a month. It is now about $154 a month at a maintenance dose between the cheapest compounded semaglutide we captured and an FDA-approved oral tablet with its own trial programme.
That is the single most useful fact on this page. Anyone choosing compounded semaglutide today on cost grounds is making a much narrower saving than the same decision made two years ago, against a product that is no longer the only affordable option.
Why is NovoCare cheaper than retail?
Same molecule, same manufacturer, different channel. NovoCare is Novo Nordisk's own self-pay programme, priced to compete with cash-pay compounding rather than against an insurer. Retail list runs roughly $1,349 because it is the price a plan negotiates down from, not one many people pay.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What if I have coverage but Wegovy is excluded?
This is the most common situation and the one most pages skip. A large share of employer plans still exclude weight-loss drugs, and the savings card reduces a copay rather than acting as a coupon — so with no copay there is nothing to reduce.
| Situation | Monthly | Why |
|---|---|---|
| Plan covers Wegovy | $0–$25 | The card reduces an existing copay |
| Plan excludes weight-loss drugs | ~$650 | A separate non-covered tier |
| Medicare or Medicaid | Card barred | Federal law. Use the Bridge at ~$50 |
| No insurance | $349 | NovoCare direct, or $149 for the approved tablet |
What should I ask before paying cash?
- Is Wegovy on my formulary, and at what tier? One call, and it decides everything above.
- What will I pay at 2.4 mg, not at the starting dose?
- If compounded, what is the salt form? Sodium and acetate are not the same active ingredient as the base in the approved products, and the FDA has said they are not appropriate for compounding.
- What is refunded if I stop during titration? About 7% of STEP-1 participants discontinued for an adverse event.
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $165 | $149 | $110 | $145 | $1,740 |
| Microdose | $129 | $117 | $114 | $110 | $1,320 |
| Sublingual ODT | $199 | $185 | $177 | $165 | $1,980 |
| Semaglutide, regular, for comparison | $165 | $149 | $110 | $145 | $1,740 |
Flat at every covered dose within each protocol. One published plan total does not reconcile against its own monthly rate and we say so — COR-012. Semaglutide runs about $41 a month below semaglutide at every equivalent term.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
How much is Wegovy without insurance?
$349 a month through NovoCare direct, against roughly $1,349 at retail list. The approved oral semaglutide tablet is $149.
Is compounded semaglutide cheaper than Wegovy?
The cheapest we captured is $145 flat, against $349 for brand. It is also about $154 a month at a maintenance dose below an approved oral tablet that has its own trial programme.
Does the savings card help without insurance?
Not at the $25 level. It reduces a copay, so with no commercial coverage there is no copay to reduce.
Related on this site
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Cheapest FDA-Approved vs Compounded GLP-1 OptionsJournal
- Brand-Name vs Compounded GLP-1Comparisons
- Zepbound vs MounjaroComparisons
- Zepbound vs Compounded TirzepatidePillar / Money
- Zepbound vs Compounded TirzepatideComparisons
- Ro Body vs Mochi HealthComparisons
- Ro Body Tirzepatide ReviewProviders
Related coverage
- Weight-Loss Percentage Calculator
- GLP-1 insurance coverage
- Prior authorization: what plans require
- Appealing a denial
- When your plan drops coverage
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Semaglutide Came Off the Shortage List in February 2025 — With a May Deadline for Outsourcing Facilities
- SOUL: Oral Semaglutide Cuts Major Cardiovascular Events by 14% in High-Risk Type 2 Diabetes
GLP-1 Semaglutide Rx. “Wegovy Cost Without Insurance in 2026: Every Route Priced.” S.J Partners LLC, 2026-08-03. https://glp1semaglutiderx.com/wegovy-cost-without-insurance-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.